Tagged with Lithuania

Baltics As the Lithuanian market matures, profound shifts have been taking place in the arena of human resources and how drug developers go about identifying, acquiring and retaining the personnel they require for a new age of medical science. “There are a number of emerging trends underway that are forcing companies…

Lithuania Lukas Savickas, advisor to the prime minister of Lithuania, highlights the changes needed for the Lithuanian life science industry to become more competitive, while discussing the opportunities awaiting companies willing to invest in the country. Can you please introduce yourself to our international audience as well as the main points…

Lithuania Lithuania’s key economic indicators between 2015 and 2018: GDP growth, inflation, unemployment rate, and government budget. Lithuania’s pharma market in terms of both volume and value. Spending on public health in Lithuania. The Lithuanian pharma market split by dispensing types. The public funding of health and pharmaceuticals in Lithuania. Healthcare…

Lithuania The Top 20 pharma companies in Lithuania by value for 2017. J&J leads the way with a value of around EUR 35 million and market share of 6.3% bolstered by 63% year-on-year growth. Berin Chemie ranks second, while Novartis ranks third.

Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…

Lithuania Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders are, however, split on whether Lithuania truly holds the potential to become a biotech hub that can stand alongside nations…

Lithuania Aki Kasvi and Mindaugas Plieskis of Janssen Baltics discuss their strategic priorities, acting as a strategic partner within the region, and ensuring that patients can access their innovative latest-generation therapies Mr Kasvi, you were nominated to head up Janssen’s Lithuanian office back in November 2017. What was the strategic mission…

Lithuania Eugenija Sutkienė of TGS Baltic, a commercial law firm operating across the Baltics, discusses the services that the organization provides to the pharmaceutical and biotech industries and what sets them apart from the competition. TGS Baltic has distinguished itself as a full-service, top-tier commercial law firm focusing specifically on the…

Lithuania Dr. Rasa Verkauskiene, a key opinion leader in endocrinology in Lithuania, discusses the levels of diabetes in the country and how various stakeholders are working together to combat what is a serious issue, affecting the lives of more than 120,000 Lithuanians. Could you please introduce yourself to our international audience?…

Lithuania Daina Klepone, managing director at Enterprise Lithuania, explains the opportunities Lithuania can offer to healthcare businesses and how their organization can help them enter the market. Moreover, she introduces the ‘Life Sciences Baltics’ event, and its key role to promote the industry in the Baltic region. Could you please start…

Lithuania Vytautas Baublys, co-founder and CEO of Softneta, introduces the award-winning Lithuanian IT company, and its service offering, explaining how software-based specialized healthcare solutions improve the quality of patient care. Further, he discusses the importance of the company’s FDA-approved platform, facilitating the communication flow between scientists, doctors and patients, allowing them…

Lithuania Jūratė Sabalienė, who was appointed in September 2017 as the director of the National Health Insurance Fund (NHIF) of the Republic of Lithuania, explains her commitment as well as the back-up strategy to ensure the access to medicines of all Lithuanian patients in a financially sustainable manner. Could you please…